Answers are grounded in this paper and cite their sources.
Clinical trial evaluates cilostazol for accelerating hematoma clearance in spontaneous intracerebral hemorrhage, highlighting potential medical strategies for stroke recovery.
Intracerebral hemorrhage (ICH) is a deadly form of stroke with no established medical treatment to promote hematoma resorption. Cilostazol accelerates hematoma clearance in rodent models by enhancing cerebral lymphatic activity. The Effect of Cilostazol for Promoting Hematoma Clearance after Intracerebral Hemorrhage (EPOCH) trial aims to evaluate if cilostazol offers similar effects in patients with spontaneous ICH.
No takes yet. Share an insight, caveat, or question.
Hsieh et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: